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Background: The unavailability of standardized parameters in bowel ultrasonography (US) commonly used in Crohn’s disease (CD) and the 
shortage of skilled ultrasonographers are 2 limiting factors in the use of this imaging modality around the world. The aim of this study is to 
evaluate interobserver agreement among experienced sonographers in the evaluation of bowel US parameters in order to improve standardization 
in imaging reporting and interpretation.
Methods: Fifteen patients with an established diagnosis of CD underwent blinded bowel US performed by 6 experienced sonographers. Prior 
to the evaluation, the sonographers and clinical and radiological IBD experts met to formally define the US parameters. Interobserver agreement 
was tested with the Quatto method (s).
Results: All operators agreed on the presence/absence of CD lesions and distinguished absence of/mild activity or moderate/severe lesions in 
all patients. S values were moderate for bowel wall thickness (s = 0.48, P = n.s.), bowel wall pattern (s = 0.41, P = n.s.), vascularization (s = 0.52, 
P = n.s.), and presence of lymphnodes (s = 0.61, P = n.s.). Agreement was substantial for lesion location (s = 0.68, P = n.s.), fistula (s = 0.74, 
P = n.s.), phlegmon (s = 0.78, P = 0.04), and was almost perfect for abscess (s = 0.95, P = 0.02). Poor agreement was observed for mesenteric 
adipose tissue alteration, lesion extent, stenosis, and prestenotic dilation.
Conclusions: In this study, the majority of  the US parameters used in CD showed moderate/substantial agreement. The development 
of  shared US imaging interpretation patterns among sonographers will lead to improved comparability of  US results among centers and 
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facilitate the development of  multicenter studies and the spread of  bowel US training, thereby allowing a wider adoption of  this useful 
technique.
Key Words:  inflammatory bowel disease, radiology/imaging, Crohn’s disease, inflammation
INTRODUCTION
The management of Crohn’s disease (CD) has evolved 
over the last 2 decades; we have a better understanding of dis-
ease progression, and it has been established that there remains 
a disconnect between disease activity as defined by persis-
tent inflammation and symptoms experienced by the patient. 
Unrecognized and uncontrolled inflammation can lead to pro-
gressive intestinal damage and complications requiring surgery. 
Therefore, improving access to monitoring strategies that are 
acceptable to patients, physicians, and society is important. 
Ideally, this would involve modalities that are safe, noninva-
sive, and readily accessible and can be delivered repeatedly at 
an acceptable cost, so that it can be integrated into close mon-
itoring strategies. Bowel ultrasonography (US) represents an 
attractive first choice imaging modality in CD because it meets 
all the criteria mentioned. Bowel US can be repeated frequently 
for lesion assessment and monitoring over time. As bowel US 
does not involve radiation and has a low cost, it provides a con-
venient alternative to other radiological techniques, especially 
in children and young patients.1–5
Much like other imaging modalities, including magnetic 
resonance (MR) and computed tomography (CT), successful 
evaluation with bowel US depends on the acquisition of certain 
skills and experience, which may vary among individual oper-
ators. The current unavailability of standardized parameters 
in CD US and the shortage of skilled ultrasonographers are 2 
limiting factors in the use of this imaging modality around the 
world. Interobserver agreement between operators with various 
degrees of experience in bowel US and its learning curve need 
to be investigated further.6–9 Preliminary results from an Italian 
study showed that bowel US signs used in CD could be stand-
ardized with fair to good reproducibility among operators.8 
Hence the aim of this pilot study is to assess the interobserver 
agreement among bowel US experts from different centers, in 
the evaluation of established bowel US parameters commonly 
used in the diagnosis and monitoring of patients with CD.
METHODS
This prospective study was performed by 6 sonographers 
and 11 clinical and radiological experts from different inflam-
matory bowel disease (IBD) centers around the world (Canada, 
United States, Germany, Japan, Italy). The study was per-
formed at Policlinico Universitario Tor Vergata in Rome dur-
ing the meeting from July 16 to 18, 2015. The median time of 
practice in bowel US for the 6 operators was 20.5 years (range, 
15–33 years), with more than 1000 exams per year. Prior to the 
evaluation of interobserver agreement, all the experts (sonogra-
phers, clinical and radiological experts) attended a 1-day meet-
ing to formally define the US signs included in the study and the 
clinical relevance of all parameters (Table 1), using both videos 
and bowel US images. All of these US parameters have been 
previously described.10–12
Patients
Fifteen consecutive patients with established CD were 
enrolled based on accepted diagnostic criteria13 of clinical, radi-
ologic, endoscopic, and histologic findings. Clinical character-
istics of patients are shown in Table 2. Patients were regularly 
TABLE 1: US Parameters Selected and Standardized by the Experts
Bowel wall thickening n.v. <3 mm for small bowel for at least 4 cm (<4 mm for colon)
Bowel wall pattern Stratification conserved or disrupted
Stenosis Coexistence of a thickened and stiff  bowel loop with the loss of wall layers and severe lumen narrow-
ing, with or without prestenotic bowel dilatation (>25 mm)
Fistula Hypoechoic track with or without hyperechoic content seen outside the bowel loop, between loops, 
or between the loop and the urinary bladder
Phlegmon Hypoechoic mass with poor margination within the inflamed echogenic perienteri fat
Abscess Roundish anechoic lesions, with an irregular wall, often presenting internal echoes and posterior 
echo enhancement
Lymph node Presence and short axis diameter >5 mm
Mesenteric adipose tissue alteration Homogenous hyperechoic tissue surrounding thickened bowel walls observed in transverse section or 
easily detected when thickening of the hyperechoic halo of mesenteric fat around the bowel wall 
was consistently greater than the thickening of the normal bowel wall
Vascularization Vascularity within the thickened bowel wall evaluated by power-Doppler
Abbreviation: n.v. = normal value.
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followed up at the IBD Unit of Policlinico Universitario Tor 
Vergata of Rome, Italy. All patients underwent CD assessment 
(ileocolonoscopy and/or MR-enterography or CT-enterography) 
within 12 months before the study. At enrollment, 5 out of 15 
patients had mild-moderate clinical activity (Crohn’s Disease 
Activity Index [CDAI] > 150), and 1 patient was admitted to our 
Gastroenterology Unit after ultrasonographic assessment due 
to presence of an abdominal abscess confirmed by CT. Eligible 
patients were aged 18 years or older and were able to give written 
informed consent. Pregnant women and patients with a body 
mass index higher than 30 were excluded. Informed consent was 
obtained from all patients. This pilot study was approved by our 
institutional ethics committee (number 93.2015).
Diagnostic Evaluation
Recruited patients underwent 6 bowel US performed by 
the 6 operators, who were blinded to all other observations in 
the same day. The operators were not blinded to the clinical, 
endoscopic, and other imaging modality characteristics of 
patients. In all recruited patients, a Case Report Form was gen-
erated for bowel US parameters by each operator. For the pur-
poses of data recording, bowel wall thickening (BWT; 3–7 mm 
vs >7 mm) (Fig. 1) and bowel wall pattern (preserved vs dis-
rupted echostratification), were recorded, and measurements 
were considered for each segment of the bowel including the 
duodenum, jejunum, ileum, terminal ileum, and colon (rectum, 
sigmoid, descending colon, transverse, ascending, and cecum). 
For each segment, operators indicated the presence or absence 
of CD, the length of the disease, the presence of complications 
including stenoses with or without prestenotic dilation (Fig. 2), 
and extra-enteric complications such as abscess, phlegmon, or 
fistulae and/or lymph nodes or mesenteric adipose tissue alter-
ation, and vascularization (absent/mild vs moderate/severe) 
(Fig.  3) was also recorded. All distinct sections of disease in 
each segment were recorded individually.
Bowel US was performed using the same ultrasono-
graphic equipment (MyLabTwice, Esaote, Genoa, Italy). A first 
evaluation of the bowel was made with a convex transducer (fre-
quency 1–8 MHz), followed by a high-frequency linear-array 
transducer (3–11 MHz). All patients fasted for 8 hours. Patients 
were positioned supine, bowel examination starting in the left 
lower quadrant with visualization of the sigmoid colon, pro-
ceeding proximally to the right lower quadrant to identify all 
the colonic segments, followed by the terminal ileum. All the 
remaining bowel loops were evaluated in each quadrant of the 
abdomen.
Statistical Analysis
Demographic data were expressed as median and range. 
Interobserver agreement was calculated using the Quatto 
method.14 The Fleiss’  K method is one of the tools used to 
test the agreement between the different examiners while being 
characterized by paradoxical behavior but has a limit distribu-
tion (Gauss’ z curve). The Quatto method, instead, tests chance 
agreement among multiple raters based on a test statistic, χ2. 
The main advantage of the test statistic χ2 is a well-established 
limit distribution when either the number of subjects or the 
number of raters is large. Agreement is considered almost per-
fect if  s ranges from 0.81 to 1, substantial if  s ranges from 0.61 
to 0.80, moderate if  s ranges from 0.41 to 0.60, poor if  it ranges 
from 0.40 to 0.21, and insufficient if  it ranges from 0.20 to 0.01.
RESULTS
No indeterminate results were obtained for the US scan 
examinations. The data were of sufficient quality to allow 
evaluation on US interobserver agreement in all patients.
In this study, all operators agreed on the presence/absence 
of CD lesions and regarding distinction of absence/mild activ-
ity vs moderate/severe lesions. Using bowel US, all operators 
detected lesions compatible with CD with moderate/severe 
TABLE 2: Clinical Characteristics of the 15 CD Patients
Sex, M/F 8/7
Median age (range), y 41 (20–64)
Smoking habits, No.
Yes 10
No 5
Median time from diagnosis (range), mo 132 (7–235)
Montreal Classification, No. (%)
Age at diagnosis A1: 4 (26.7)
A2: 8 (53.3)
A3: 3 (20)
CD location L1: 10 (66.7)
L2: 0 (0)
L3: 5 (33.3)
L4: 0 (0)
CD behavior B1: 1 (6.7)
B2: 10 (66.7)
B3: 4 (26.6)
Previous surgery, No.
Yes 5
No 10
Previous exposure to anti-TNFs, No. (%) 6 (40)
Median CDAI at enrollment (range) 110 (50–310)
Median CRP level at enrollment (range), mg/L 5 (1–47)
Therapy at enrollment, No.
Mesalamine 4
Corticosteroids 3
Thiopurines 2
Infliximab 2
Adalimumab 3
Corticosteroids + adalimumab 1
Abbreviations: anti-TNF  =  anti–tumor necrosis factor; CDAI  =  Crohn’s Disease 
Activity Index; CRP, C-reactive protein.
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activity in 14 out of 15 patients. Further, in 1 patient, all the 
sonographers detected no lesions and no activity.
S values were moderate for bowel wall thickness (k = 0.48, 
P = n.s.), bowel wall pattern (s = 0.41, P = n.s.), vasculariza-
tion (s = 0.52, P = n.s.), and presence of lymph nodes (s = 0.61, 
P = n.s.). Figure 4 showed agreement in detecting bowel wall 
thickness measurements and evaluation of bowel wall pattern 
(9 mm and preserved for both sonographers) in a patient with 
ileal CD.
Agreement was substantial for lesion location (s = 0.68, 
P = n.s.), fistula (s = 0.74, P = n.s.), and phlegmon (s = 0.78, 
P =  0.04), and it was almost perfect for abscess (s  =  0.95, 
P = 0.02). Poor and insufficient agreements were observed for 
mesenteric adipose tissue alteration (s = 0.35, P = n.s.), lesion 
extent (s = 0.26, P = n.s.), stenosis (s = 0.19, P = n.s.), and prest-
enotic dilation (s = 0.36, P = n.s.).
DISCUSSION
Transabdominal US is considered a useful technique for 
the assessment of bowel inflammation.9 In a systematic review 
conducted by Panés and colleagues, no significant differences 
in diagnostic accuracy among the imaging procedures (bowel 
US, CT, MR) were observed, and the authors concluded that 
because patients with IBD often need frequent re-evaluations 
of disease status, use of diagnostic modalities that are safe, with 
FIGURE 1. Long axis (A) and axial images (B) of the terminal ileum.
FIGURE 2. The white arrows indicate bowel wall thickness and stenosis 
of the terminal ileum associated with prestenotic dilation.
FIGURE 3. Power-Doppler ultrasound image of the affected CD seg-
ment shows moderate mural blood flow.
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avoidance of ionizing radiation, is preferable. Ultrasonography 
is an accurate modality, readily available and inexpensive, and 
given repeatability, findings may help to expedite the objective 
and facilitate targeted therapy.
Although typical morphological imaging findings have 
been described in detail and reported in the literature with 
extensive comparisons of US with other techniques,3–5, 9, 10 
the consistency of interobserver agreement is still a matter of 
debate. The evaluation of the interobserver agreement is par-
ticularly relevant in bowel US, a technique whose results are 
strictly dependent on the operator’s experience and on the 
possible different interpretations of US features. Preliminary 
results from an Italian study suggest that bowel US signs used 
in CD can be standardized, showing fair to good reproducibil-
ity among 6 different operators (interobserver agreement was 
calculated using kappa statistics for qualitative variables). In 
particular, BWT showed excellent reproducibility.8 Therefore, 
in bowel US, it is mandatory to establish a standardization of 
the most frequently used US parameters.
In this international study, the majority of  the US 
parameters used in CD patients showed moderate/substan-
tial agreement. The development of  a standardized US 
imaging interpretation and reporting pattern among bowel 
sonographers will improve comparability of  US results 
among various centers globally, with a subsequent improve-
ment in the quality of  multicenter US studies and bowel US 
training with a wider dissemination of  this technique. All 
operators agreed on the presence or absence of  CD lesions 
and the identification of  activity in all patients. Agreement 
in scoring of  individual parameters (bowel wall thickness, 
bowel wall pattern, vascularization, lymph nodes) was mod-
erate. Improvement of  interobserver agreement is to be 
expected with enhanced operator session training, agree-
ment on approach, and standardization of  guidelines for 
identification of  bowel lesions.
Reporting of stenosis and prestenotic dilation was not 
robustly reproducible between operators. This result could be 
related to the definition of stenosis, as this is debatable. Using 
bowel US, stenosis may be defined as thickened bowel walls 
associated with a narrowed lumen and increased lumen diam-
eter of the proximal loop. A standardization of lumen diameter 
at the level of stenosis, lesion length, and prestenotic dilation 
diameter could help to better identify lesion compatibility with 
stenosis and prestenotic dilation in comparison with bowel con-
tractions or other possible lesions. This result could be related 
to the short discussion during the prededicated meeting on this 
complication. Although the use of polyethylene glycol (PEG) 
solution may lead to a significantly greater accuracy of bowel 
US in detecting the presence and number of stenoses,5, 6, 9 its use 
has not been widely adopted among the experts.
Agreement was substantial for site lesion, fistula, and 
phlegmon, and it was almost perfect for abscesses. Regarding 
the site of the lesion, high S values were observed both for the 
ileal and for the colonic tract. A very elevated level of reproduc-
ibility was reached for the presence of penetrating complica-
tions. This high level of agreement could possibly be attributed 
to well-defined parameters used to differentiate fistulas from 
phlegmon and abscesses. These results foster increased confi-
dence in the use of bowel US in different centers in severe acute 
cases of CD with high clinical suspicion of septic complications 
(such as an abdominal mass or fever). In these settings, the use 
of US at the bedside during clinical assessment as a point-of-
care method could be crucial in quickly resolving diagnostic 
questions and directing physicians to the most appropriate 
management.15,16
Use of oral and/or intravenous contrast agents and elasti-
city in addition to our US tool kit has led to an improvement in 
detecting complications in CD. Contrast-enhanced ultrasound 
(CEUS) can be used to quantify vascularity,17 but it can also be 
used to separate vascular from avascular tissue, which is par-
ticularly useful when trying to differentiate a phlegmon from 
an abscess.18 The accuracy for assessing lesions in the proximal 
small bowel for defining the extent of diseased ileal walls and 
improving stenosis detection can be significantly improved using 
an oral contrast agent (small intestine contrast ultrasonogra-
phy).5, 9 Elasticity imaging based on strain under deformation 
FIGURE 4. Example of agreement in detecting bowel wall thickness in a patient with ileal CD.
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and elastic modulus has been clinically applied for the evaluation 
of bowel lesions in CD; this technique could be a noninvasive 
tool to differentiate the nature of bowel strictures in vivo.19, 20 
Despite the small sample sizes of the available studies, elastogra-
phy has showed extremely promising results in the field of CD. 
Validating the strain elastography technique in larger cohorts is 
needed in order to confirm its very promising results, especially 
as regards its prognostic value and possible role as a predictor of 
response to treatment in CD patients.21 Multicenter studies are 
needed to evaluate all these US methods, both in characterizing 
CD lesions and in assessing interobserver variability.
Our study had some limitations. One is the relatively small 
sample size, which may lead to the underestimation of the agree-
ment for some parameters; this would benefit from evaluation 
with a larger series of patients. The sample size of interobserver 
agreement is agnostic of previous studies or data and only 
depends on the number of observers and number of items rated. 
The second limitation could be the need to better standardize 
and predefine ultrasonographic parameters. Standardization of 
the measurement of US parameters as well as interpretation of 
the findings will likely further improve intra- and inter-reader 
variability. The lack of well-defined parameters is not a limita-
tion of the present study as our aim was to assess the reproduc-
ibility of the technique and not its diagnostic accuracy, which 
has already been extensively demonstrated both in the diagno-
sis and monitoring of CD patients. The lack of well-defined 
parameters and the lack of reference standard to confirm US 
results are not limitations of this pilot study, as our aim was to 
assess the interobserver agreement of the technique and not its 
diagnostic accuracy, which has already been extensively assessed 
both in the detection and follow-up of CD patients.15
In conclusion, most of the US parameters used in CD 
patients showed moderate/substantial agreement. Good inter-
observer agreement is crucial in order to obtain a standardized 
definition of the most useful US parameters for the diagnosis 
and monitoring of CD patients. In fact, the development of 
a common US imaging interpretation pattern among bowel 
ultrasonographers around the world assessing patients with 
CD or IBD makes the development of a bowel US training 
program feasible in the near future and will allow widespread 
adoption of this technique.
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